Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 20 IN PLASTIC CONTAINER versus TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 25 IN PLASTIC CONTAINER.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 20% IN PLASTIC CONTAINER vs TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Travasol 2.75% with electrolytes in dextrose 20% provides amino acids for protein synthesis, dextrose as a caloric source, and electrolytes for maintenance of fluid and electrolyte balance. Dextrose stimulates insulin release, promoting cellular uptake of glucose and amino acids, while electrolytes help maintain osmolality and acid-base balance.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 25% is a parenteral nutrition solution providing calories (dextrose), amino acids (for protein synthesis), and electrolytes for maintenance of acid-base balance and cellular function. Dextrose is metabolized to glucose, which undergoes glycolysis and oxidative phosphorylation. Amino acids are used for protein synthesis and as an energy source. Electrolytes correct or prevent deficiencies.
Intravenous infusion: Typical adult dose is 1-2 L/day of TRAVASOL 2.75% with 20% dextrose, administered as continuous infusion via central line. Rate should be adjusted based on metabolic and fluid needs.
Intravenous infusion only. Adult dose determined by nutritional requirements and metabolic tolerance. Typical dose: 500-2000 mL/day infused continuously or intermittently, with dextrose dosage not exceeding 0.5 g/kg/h. Final concentration of dextrose and amino acids must be monitored.
None Documented
None Documented
Not applicable; TRAVASOL is a mixture of dextrose, electrolytes, and amino acids with no defined terminal elimination half-life as individual components are metabolized or excreted rapidly.
Dextrose: rapid, minutes (insulin dependent); amino acids: 20-30 min for free pool turnover; electrolytes: distribution half-life 2-4 hours, elimination depends on renal function. Clinical: continuous infusion maintains steady state.
Renal: 100% as free water, electrolytes, and dextrose metabolites; no biliary or fecal elimination.
Primarily renal (glomerular filtration). Dextrose is completely metabolized; electrolytes (sodium, chloride, potassium, calcium, magnesium, acetate) are excreted via kidneys. Acetate is metabolized to bicarbonate. No significant biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution